The techbio company Generare has announced that it has raised €20m in Series A funding co-led by Alven and Daphni with participation from all existing investors, including Galion.exe, Teampact Ventures and VIVES Partners.
The company generates novel, high-quality molecular data for drug development by "decoding what life wrote," becoming the most prominent platform generating evolution-based molecular data that "the world has been missing."
Its proprietary tech has revealed 200 previously uncharacterised small molecules, with a hit rate matching that of the most successful drug discovery programmes in history.
The new funding will be used to increase Generare's drug discovery compound library, grow its world-class team and scale its proven discovery platform to meet growing demand from pharmaceutical giants and agrochemical companies.
Why this matters
Not yet a Subscriber?
This is a small extract of the full article which is available
ONLY to premium content subscribers.
Click below to get premium content on Manufacturing Chemist.
Subscribe now
Already a subscriber?
Sign in here.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.